138 related articles for article (PubMed ID: 20600147)
1. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.
Flaquer M; Lloberas N; Franquesa M; Torras J; Vidal A; Rosa JL; Herrero-Fresneda I; Grinyó JM; Cruzado JM
Life Sci; 2010 Jul; 87(5-6):147-53. PubMed ID: 20600147
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
Lloberas N; Cruzado JM; Franquesa M; Herrero-Fresneda I; Torras J; Alperovich G; Rama I; Vidal A; Grinyó JM
J Am Soc Nephrol; 2006 May; 17(5):1395-404. PubMed ID: 16597691
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin prevents early steps of the development of diabetic nephropathy in rats.
Yang Y; Wang J; Qin L; Shou Z; Zhao J; Wang H; Chen Y; Chen J
Am J Nephrol; 2007; 27(5):495-502. PubMed ID: 17671379
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.
Wittmann S; Daniel C; Stief A; Vogelbacher R; Amann K; Hugo C
Transplantation; 2009 May; 87(9):1290-9. PubMed ID: 19424027
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
[TBL] [Abstract][Full Text] [Related]
7. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Arora MK; Reddy K; Balakumar P
Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
[TBL] [Abstract][Full Text] [Related]
8. [Effect of selective cyclooxygenase -2 inhibitor on the renal lesion of streptozotocin-induced diabetic rats and its possible mechanism].
Zuo Y; Gu Y; Ma J; Lin S
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):239-43. PubMed ID: 11953170
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats.
Weissgarten J; Berman S; Efrati S; Rapoport M; Averbukh Z; Feldman L
Nephrol Dial Transplant; 2006 May; 21(5):1198-204. PubMed ID: 16449288
[TBL] [Abstract][Full Text] [Related]
10. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
[TBL] [Abstract][Full Text] [Related]
11. Ethyl pyruvate ameliorates albuminuria and glomerular injury in the animal model of diabetic nephropathy.
Ju KD; Shin EK; Cho EJ; Yoon HB; Kim HS; Kim H; Yang J; Hwang YH; Ahn C; Oh KH
Am J Physiol Renal Physiol; 2012 Mar; 302(5):F606-13. PubMed ID: 22129969
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Russo LM; del Re E; Brown D; Lin HY
Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
[TBL] [Abstract][Full Text] [Related]
13. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
[TBL] [Abstract][Full Text] [Related]
14. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Rose M; Balakumar P; Singh M
Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
[TBL] [Abstract][Full Text] [Related]
15. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy.
Awad AS; Huang L; Ye H; Duong ET; Bolton WK; Linden J; Okusa MD
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F828-37. PubMed ID: 16332931
[TBL] [Abstract][Full Text] [Related]
17. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription.
Liu IM; Tzeng TF; Liou SS; Chang CJ
J Ethnopharmacol; 2009 Jul; 124(2):211-8. PubMed ID: 19397971
[TBL] [Abstract][Full Text] [Related]
18. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
[TBL] [Abstract][Full Text] [Related]
19. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice.
Wang LH; Liu JS; Ning WB; Yuan QJ; Zhang FF; Peng ZZ; Lu MM; Luo RN; Fu X; Hu GY; Wang ZH; Tao LJ
Pharmacology; 2011; 88(1-2):88-99. PubMed ID: 21847000
[TBL] [Abstract][Full Text] [Related]
20. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
Mizuno S; Nakamura T
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
